Team Sky Takes One-Two at Tour Down Under’s Cancer Classic Crit Opener

first_imgTeam Sky made one heck of a professional bike race debut today at the Santos Tour Down Under.  The new British team made a compelling case for being invited to the Tour de France by moving their paceline to the front of the pack somewhere in the two-to-go lap.Pulling at a ferocious pace, Sky’s Russell Downing pushed the needle into the red zone before moving aside for teammate Matthew Hayman to lead out.  Columbia-HTC started coming around, almost blocking Sky’s riders against the barriers, but the boys in black-and-blue came back around and Chris Sutton led Greg Henderson to victory, giving Team Sky first and second in the opening Cancer Classic Criterium.“It does not get any better than that,” said Henderson. “We were joking about winning today and putting ourselves out there on the map for the new sponsor.“They are an unbelievable team, I dont think I have ever been on a lead out that was as fast as that. In the end my job was pretty easy, I just followed Chris Sutton and the rest of the fellas. Wow what a feeling.”The pace and tactics were more than expected given that the results from today’s crit don’t add to the overall time or points for the Tour Down Under, and it’s clear that Team Sky came to play.Armstrong, meanwhile, showed real strength in a mid-race five-person breakaway, saying he felt “better than last year.”“I felt like I tested them a little bit,” said Armstrong. “We had a few good weeks in Hawaii so I know I’ve got a bit of power, but sometimes it’s better to be up on those small groups than to be back fighting with 100 guys for every wheel and every corner.“Everybody was completely going for it, no talking and only a little bit of looking around after the corners to see how close they were,” he added. “You get inside 10 (laps to go) and then to seven and six and you think ‘uh oh’ … if there’s a crash in the field, if two teams can’t get together or don’t get together, you just never know.“…I certainly felt better today than last year – but last year in this event I felt a little like a monkey screwing a football, too,” he said. “It was not pretty last year, this year was a little more comfortable.”Photo by Graham Watson.  Check out his full gallery from today’s event here.last_img read more

Out of their Powerlogic Lab, rh+ Speed brings aero kit from bibs to helmet

first_imgAn rh+ aero rain jersey aims to do away with flapping in the wind when the weather turns foul, and get the same aero add-on benefit. The 120€ SpeedRain shell is a compromise between a rain vest and a rain jacket in what is essentially a 3/4 sleeve wet weather jersey. It gets similar on-the-bike pre-shaping (especially around the neck), but here uses a 4-way Polyester stretch fabric that still claims 10,000 mm/ca waterproofing. It gets taped seams around the shoulder and arm to keep water out where it really matters. The heart of the Speed line is the SpeedCell jersey. Developed to limit drag, it uses a well-formed and pre-shaped fit tailored for an aggressive on-the-bike position. It combines a DrySkin front with a textured Dual Cell back, and adds a 3D mesh panel at the back that together create a slippery jersey that minimizes drag of the rider’s back. Pockets are streamlined to lay flat out of the wind and sleeves are cut long with a flat finish end to transition smoothly to the lower bicep. The 150€ jersey is available in black, grey, and white. The new Speed line from rh+ comes out of more development and testing with their Fundación Contador development team. The product of the in-house rh+ technological development group at their Powerlogic Lab, Speed was a project to bring together aerodynamics, temperature regulation, and overall comfort to a broader range of users than just road pros. Rh+ sees the benefit of aero improvements across all types of riding, especially for things like granfondo racing, XC and marathon racing where cyclists often spend a lot of time out on their own, but aerodynamics have traditionally been ignored. The Speed line-up starts with an aero cut SpeedCell jersey and bibs, and expands tin include a rain shell jacket and paired helmet and sunglasses. Take a closer look at each after the break…images courtesy of rh+Rh+ designed the Speed line around the needs of cyclists in general, not just their discipline. As such every cyclist can benefit from better fitting and better performing kit. That said, by sponsoring the rh+ Polartec Fundación Alberto Contador Team, rh+ has been able to pull in the expertise from developing their team race kit and having the chance to properly test it in real riding conditions. To complete the aero rh+ Speed setup, they suggest adding the newly introduced fast Z Alpha helmet. Rh+ claims that the MIPS helmet delivers much better aerodynamics than typical helmets, and way better ventilation than current aero offerings. That places it somewhere in between, as a happy medium style helmet for all types of riding. Top it off with a pair of 135€ Olympo Triple Fit shades. The glasses build adjustability into their nose piece and temples to ensure a close and comfortable fit, keeping the wind out.zerorh.com The SpeedCell bib shorts use the same waffle textured Dual Cell fabric on the sides to break up air as it passes over the rider’s spinning thighs, and a 3D mesh back and bib straps to keep cool. The 175€ bibs use Elastic Interface’s new Lìege dual-density chamois for long ride comfort on either road or trail, and also add nice little features like a rear radio pocket, reflective details, and seams that are claimed to sit especially flat. Like the jersey, the bibs are available in this grey, a similar white with red accents, and an all-black version.last_img read more

Men’s Hockey loses 2-1 in OT

first_imgMen’s Hockey loses 2-1 in OTTigers forward Chad Rau scored both of CC’s goals. Brian DeutschOctober 19, 2007Jump to CommentsShare on FacebookShare on TwitterShare via EmailPrintColorado Springs – Colorado College hadn’t swept Minnesota since December 2005, but a night after snapping a six-game losing skid to Minnesota, the Tigers started a streak of their own ñ edging the Gophers 2-1 in overtime tonight in front of a sold-out home crowd at the World Arena.“Our emphasis was coming out and competing tonight and I think we did that pretty well,” Junior forward Blake Wheeler said. “Sometimes you come up on the short end of the stick when that happens.Wheeler put the Gophers up 1-0 at the 4:24 mark of the second period when he put a back-handed rebound under freshman net-minder Richard Bachman. Senior forward Ben Gordon and sophomore forward Ryan Flynn assisted on the play.But the Tigers struck back later in the period after sophomore Brian Schack was whistled for high sticking ñ giving CC a man advantage.The Tigers were also helped when sophomore defensemen Nate Prosser caught the Gophers in the middle of a line change ñ finding forwards Scott McCulloch and Chad Rau for the 2-on-0.A last second pass from McCulloch found Rau with an open shot, and the Eden Prairie native score his first goal of the year past a sprawling Jeff Frazee in goal for Minnesota.Once again penalties plagued the both teams – __ were called over the 60 minute conflict.But just like the night before, the Tigers were the only team to take advantage of the opportunities ñ converting one their four chances. Meanwhile the Gophers were again blanked on the power-play failing to convert any of their eight opportunities in the game.Minnesota has failed to score on its last 15 power-play chances dating back to the RPI game.Frazee and Bachman both played solidly between the pipes stopping a combined 59 of 61 shots in regulation ñ including 21 shots turned away by Bachman in the third period alone.“It easily could have been 5-5 at the end of regulation, both goalies were outstandingÖ” Gophers coach Don Lucia said. “It just seemed like any time somebody got an opportunity, the goalie was there to make the save.”In the end, Minnesota resorted to simply teeing up with slap shots in hopes of beating the Tigers net-minder but to no avail as the game went into overtime.“We put close to 40 shots on the kid and he gave up one goal. We had some great scoring opportunities on him and he shut the door,” Wheeler said. “They played a great game, and he was a big part of that.”In the extra period, Colorado College played dominant hockey, out-shooting the Gophers 4-1 including the game-winning goal off the stick of Rau.The junior forward tipped in a pass from sophomore defenseman Kris Freheim to end the game and tally his second goal of the night.last_img read more

H1N1 mutation’s proposed link to severe illness debated

first_imgMar 4, 2010 (CIDRAP News) – Norwegian scientists today reported a pandemic H1N1 virus mutation that appears to be associated with severe disease, but a leading US flu expert said global data on the mutation don’t show a clear connection with severe illness.A team from the Norwegian Institute of Public Health in Oslo reports that it found the mutation in 11 of 61 severe illness cases that were analyzed between July and December 2009. The mutation was not found in any of 205 mild cases that were analyzed between May 2009 and January 2010.”This difference is statistically significant and our data are consistent with a possible relationship between this mutation and the clinical outcome,” says the report by A. Kilander and colleagues, published today in Eurosurveillance. “To our knowledge, this is the first identification of a change in the pandemic virus that correlates with a severe clinical outcome.”However, Dr. Nancy Cox, director of the Influenza Division at the US Centers for Disease Control and Prevention (CDC), said global H1N1 data so far do not show a clear association between the mutation and severe illness.”If you look globally you can see that this mutation is neither necessary nor sufficient for a severe or fatal outcome,” Cox told CIDRAP News.The mutation the Norwegians found in the severe cases is called D222G (a change from aspartic acid to glycine in position 222 in the HA1 subunit of the hemagglutinin protein), according to the report. The team found it by sequencing viruses from the 61 severe cases and 205 mild cases. D222G mutant viruses were detected in severe cases throughout the sampling period of July to early December.Because the mutation is found in the receptor binding site of hemagglutinin, it may influence which types of cells and which parts of the respiratory tract the virus binds to, the report says.”Our observations are consistent with an epidemiological pattern where the D222G substitution is absent or infrequent in circulating viruses, with the mutation arising sporadically in single cases where it may have contributed to severity of infection,” the scientists write.They suggest that the mutation may increase the virus’s ability to bind to lung cells, leading to more severe illness. But it is also possible, they say, that the mutation is more likely to occur in patients who fail to fend off the virus quickly and end up with the infection in their lungs.A “large proportion” of the patients with severe cases had underlying health conditions that increased their risk, but some of the patients were previously healthy and had an initially mild illness that later became much more severe, the report says.”We consider it likely that there is a causal relationship between the occurrence of the D222G mutation in this virus and severe disease,” it states. But it adds that the mutation is clearly not required for a severe outcome, since most of the severe and fatal cases did not feature it.Cox, however, said it’s too soon to conclude there is a causal relationship. She pointed to possible holes in the Norwegian analysis, along with global surveillance data and experimental data.”They haven’t adjusted for a whole variety of confounders that could influence the appearance of the mutation, such as time between onset of illness and collection of specimens, which might differ in mild and severe cases,” she said. Another possible confounder, she added, is the fact that some of the patients with severe illness had underlying conditions, which increase the risk of severe flu.Some countries have reported the D222G mutation only in mild cases, while others have seen it as statistically linked with severe illness, but the latter didn’t rule out possible confounders, Cox said. She reported that the CDC has found the mutation in a total of eight cases, of which five were nonfatal. Some of the nonfatal cases were mild.Cox also said a lab experiment in ferrets did not support a causal link with severe disease. Virologist Dr. Richard Webby infected ferrets with a wild-type H1N1 virus or with a strain virus engineered to contain the D222G mutation, and found that those infected with the mutant strain had no worse disease than the others, she said.”So, so far what’s been done in animal models doesn’t reflect the association of severity with this mutation,” Cox said.Referring to the Norwegian report, she commented, “It’s intriguing, and there could be some association, but it’s certainly not as clear as they’ve painted it.””I think additional work needs to be done before we conclude that there is a causal relationship,” she said.Kiland A, Rykkvin R, Dudman SG, et al. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Eurosurveillnace 2010 Mar 4;15(9):2 [Full text]See also: Nov 20, 2009, WHO statement on previous report of mutation seen in severe cases in Norwayhttp://www.who.int/csr/disease/swineflu/notes/briefing_20091120/en/index.htmllast_img read more

FDA warns about hydroxychloroquine, chloroquine for COVID-19

first_imgThe Food and Drug Administration (FDA) today issued a warning on the use of the antimalaria drugs hydroxychloroquine and chloroquine for treating COVID-19.The warning is related to the potential for the drugs to prolong the QT interval—a cardiogram measurement used to assess some of the electrical properties of the heart—and cause abnormal heart rhythms, particularly in patients with cardiac conditions. Those risks may increase when the drugs are combined with the antibiotic azithromycin, which can further increase the risk for sudden cardiac arrest.Hydroxychloroquine and chloroquine, either alone or in combination with azithromycin, are being studied for COVID-19 but are also increasingly being prescribed to COVID-19 patients outside the hospital setting. The FDA says use of the drugs should be limited to clinical trials or for treating certain hospitalized patients under the agency’s Emergency Use Authorization (EUA), which was issued in late March.”The FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines,” the FDA said in its drug safety communication.”Therefore, we would like to remind health care professionals and patients of the known risks associated with both hydroxychloroquine and chloroquine. We will continue to investigate risks associated with the use of hydroxychloroquine and chloroquine for COVID-19 and communicate publicly when we have more information.”Because of the potential for these adverse side effects, treatment guidelines issued by the National Institutes of Health earlier this week also recommended against the use of hydroxychloroquine or chloroquine in COVID-19 patients, either alone or in combination with azithromycin, outside of clinical trials.Study raises red flagsThe heart issues associated with use of hydroxychloroquine and chloroquine in COVID-19 patients are highlighted in a study published today in JAMA Network Open. The findings are from one of the many clinical trials being conducted to determine the safety and efficacy of the drugs in treating COVID-19.In the study, researchers from Brazil and Spain report that a high dosage of chloroquine given to COVID-19 patients at a Brazilian hospital was associated with more patient deaths than a low dose of the drug, and that a higher percentage of high-dose patients experienced prolongation of the corrected QT (QTc) interval. The patients were taking part in the phase 2b randomized CloroCovid-19 trial, which had a target of 440 patients but was terminated after only 81 patients were enrolled, based on the occurrence of adverse events.Of the 81 patients enrolled in the double-blind, randomized trial, 41 were allocated to a high-dosage group that received 600 milligrams (mg) of chloroquine (CQ) twice daily for 10 days, and 40 were in a low-dosage group that received 450 mg of CQ twice daily for 1 day and once daily for 4 days. All patients also received azithromycin, and 92.5% of the high-dosage group and 86.8% of the low-dosage group received the flu antiviral drug oseltamivir (Tamiflu).All patients in both groups had severe illness, and post-enrollment testing confirmed COVID-19 in 75.6% of the high-dose patients (31 of 41) and 77.5% of the low-dose group (31 of 40). The patients in the high-dosage group were older than those in the low-dosage group (mean age 54.7 years vs 47.4 years) and had more heart disease (17.9% vs 0%).The primary outcome of the trial was death by day 28, with the working hypothesis that the lethality rate in the high-dosage chloroquine group would be half that of the low-dosage group.Preliminary analysis on day 13, however, found that 39% of the high-dosage patients (16 of 41) had died, compared with 15% of the low-dosage patients (6 of 40). In addition, a QTc interval of greater than 500 milliseconds was observed in 18.9% of high-dosage patients (7 of 37), compared with 11.1% of the low-dosage patients (4 of 36). But the researchers said they found no clear association between the appearance of QTc interval prolongation and death.Based on these results, an independent data and safety monitoring board recommended ending the enrollment of patients in the high-dosage group, and all patients were moved to the low-dosage group.”In the context of patients with severe COVID-19, our study raises enough red flags to stop the use of a high-dose regimen (ie, 12 g of CQ during 10 days), because the risks of toxic effects overcame the benefits,” the authors wrote.They note, however, that since all patients were also receiving azithromycin and most were on oseltamivir (which also increases the QTc interval), they could not independently assess the toxic role of chloroquine. Another limitation is that the high-dosage group had more patients who were susceptible to cardiac complications.”In any case, use of CQ in older patients, especially those with heart disease, should be conducted with caution,” they said.Skepticism needed, experts sayIn an editorial that accompanies the study, a trio of experts from the University of Washington, University of Iowa, and the Minneapolis Heart Institute say that, because of the noted limitations, the only conclusion that can be made is that high doses of chloroquine, in combination with azithromycin and potentially oseltamivir, are potentially associated with increased mortality in patients with severe COVID-19.But they argue that the results should dampen some of the hype about hydroxychloroquine and chloroquine, both of which have been touted by the Trump administration and some media outlets as an effective treatment for COVID-19 since the results of an uncontrolled French study published in March suggested the drugs had a potential antiviral effect. Despite warnings from several health experts about the need for more evidence of efficacy, including National Institute of Allergy and Infectious Diseases Director Anthony Fauci, MD, thousands of patients are now taking the drugs as part of their treatment, according to the Wall Street Journal.The authors say they hope the ongoing clinical trials will provide more information about the efficacy and safety of the drugs.”In the interim, the results of this trial…should prompt some degree of skepticism toward the enthusiastic claims about chloroquine and perhaps serve to curb the exuberant use,” they wrote. “For the time being, prudent clinicians should discuss with patients and their families, when feasible, the potential risks of this drug and the uncertain benefits before initiating it.”last_img read more

Meritor’s ‘First Woman’ Retires After 65-Year Career

first_imgTROY, Mich. — Meritor Inc. is hosting a celebration in honor of its longest serving employee: Loraine Simler. Simler, a sales representative in Meritor’s Aftermarket & Trailer division, is retiring this month after 65 years with the company.   Simler blazed a trail for many women to follow at Meritor. She has been witness to and participated in many firsts, including becoming Meritor’s first-ever female manager in 1965 when she was named a buying manager. She joined the company in 1946 as a file clerk/typist, when the company was known as Timken Axle. In 1953, she became a secretary in the purchasing department. It was a few years after that she became part of the company’s history.   “I was the first person to use an electric typewriter at this company,” Simler said. “It made me a lot faster when it came to typing invoices. I also used the first computer here.”   After several years as a buying manager, she moved into the aftermarket parts division in 1973. Since then, she has held positions of increasing responsibility within Meritor before she settled into her current job in 1983 as a sales representative for the aftermarket division. In 2006, she was rewarded for her many years of service with her own parking spot at the Troy, Mich., campus.   Yesterday, the company honored Simler with “Loraine Simler Day.” She rode to work at the company’s headquarters in a limousine, where she was met by Chip McClure, chairman, CEO and president, as well as other members of senior management, who escorted her down a red carpet in to the building, draped with a banner expressing thanks for her contributions to Meritor.   “Spending 65 years at the same company is something so rarely achieved these days,” said Joe Mejaly, president, Aftermarket & Trailer, Meritor. “It’s important to acknowledge events like this and we’re excited to recognize Loraine’s time at Meritor.   Hundreds of employees and friends gathered in the company’s auditorium yesterday morning to celebrate her career, featuring a video with more than a dozen current and former colleagues relating stories about Loraine as well as gifts showing the company’s appreciation for her years of service.   “I’ve enjoyed my time here,” she said. “I consider everyone here part of my family.”   Simler is not alone in her dedication to her job and the company. Gilbert Wilson, a hi-lift driver at Meritor’s Newark, Ohio facility, celebrated his 80th birthday in October. He hired into the Newark facility on March 31, 1952. He has 59 years of service with the company and has let it be known that he has “an eye on Loraine’s record.”  AdvertisementClick Here to Read MoreAdvertisementlast_img read more

Exclusive interview with Carbon Engineering CEO

first_imgGet instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270. Subscribelast_img

Double success for ASCO in Norway

first_imgThe company has also signed a supply base partnership deal with Maersk Oil to support its drilling campaigns in Norway over the next three years.Due to be operational from mid 2013, the Tromsø base will be the focal point for servicing rigs in the north Norwegian Sea.Work to construct the supply base facility has started, on the brown field site which is just south of Hammerfest.The Tromsø development is part of a NOK300 million (USD49.5 million) development plan by the port authority. It comes in direct response to increased oil and gas activity in the far north of Norway.ASCO’s northern Europe managing director, Runar Hatlevedt, said, “Tromsø is a key logistics hub in northern Norway, strategically situated on the edge of the Arctic. This is a very important area of development for us and will enable us to support key drilling operations in the northern part of the Norwegian Sea.”The site will comprise of 80,000 sq m of industrial space and two deep water quaysides in excess of 200 m.Hatlevedt added, “We are very impressed at the infrastructure being created by the port authority. This type of infrastructure is so important for global companies such as ASCO to establish our operations for the major oil and gas operators. In addition, our partnership with Tromsø Port Authority will help create jobs in the local area as well as develop local skills – boosting the local economy.”The cooperation agreement also allows ASCO to commence logistics operations immediately at existing Tromsø Port facilities.ASCO Norway has also signed a three year partnership deal to support Maersk Oil’s drilling campaigns in Norway. The campaigns will be supported from ASCO’s Kristiansund base at Averøy. The first oil rig to be supported under the new contract will be the Transocean Barents at license 6506/6-2 Albert in the Norwegian Sea just north of Kristiansund.www.ascoworld.comlast_img read more

XL introduces universal charger

first_imgAccording to XL Lifts, universal battery chargers can power multiple product lines and brands of forklifts. The weather-resistant design means forklifts can be charged outdoors, said XL Lifts.“We are ecstatic to offer our customers a forklift battery charger that is flexible in its design and its configuration,” said Mike Marzahl, president of XL Lifts. “Our XLerator battery chargers will free companies from the current constraints of powering electric material handling equipment and ultimately save them both time and money.”xlliftsinc.comlast_img read more

Doll based on transgender teen to debut at New York Toy Fair

first_img Author: AP Do you see a typo or an error? Let us know. SHARE Published: February 10, 2017 4:14 PM EST center_img Doll based on transgender teen to debut at New York Toy Fair WASHINGTON (AP) – A New York doll maker says it will be selling what it believes is the first transgender doll on the market.The doll is based on Jazz Jennings, the teenage transgender subject of the TLC documentary series “I am Jazz.” It will make its debut at the New York Toy Fair next week and be available on the Tonner Doll Co.’s web site and in specialty stores in July.A spokesman for the company said the 18-inch doll, which has a “genderless” plastic mold typical of most dolls, is being tested for kids aged 8 years and older and is expected to retail for $89.99.In comparison, the popular mass-market “American Girl” 18-inch dolls, which come with a book, sell for $115 on AmericanGirl.com.Tonner Doll, which is based in Kingston, New York, said Friday that the “Jazz” doll is being launched as a test for the specialty-retail market and will be sold by 25 to 50 stores. If it’s a hit, the company hopes to take it to the mass market.The doll was designed and sculpted by company founder Robert Tonner. His company has made dolls based on a variety of TV, film and book characters including Spiderman, Harry Potter, Dr. Who and Wonder Woman.“Jazz stands for everything I respect from a human nature point of view – she’s incredibly brave, intelligent, warm-hearted and creative,” Tonner said.Jennings appeared at age 6 on a Barbara Walters 20/20 special in 2007. She has identified as a female since she could talk, her parents told ABC News.She is the youngest person ever to be recognized in The Advocate Magazine’s “Top Forty Under 40” annual list and was named as one of Time Magazine’s Most Influential Teens for 2014 and 2015.In 2014, Jennings co-wrote a children’s picture book titled “I Am Jazz” and her memoir, “Being Jazz: My Life as a (Transgender) Teen,” was released last summer.The Jazz Jennings doll comes 40 years after the release of the “Gay Bob” doll, widely thought to be the first doll based on a gay character.last_img read more